CLINICAL EFFICACY OF COMBINED NEUROPROTECTION IN PATIENTS WITH COVID-19 DISEASE

Mualliflar

  • M. M. Yuldasheva Tashkent Pediatric Medical Institute Muallif

Abstrak

This article discusses the clinical efficacy of combined
neuroprotection in patients with COVID-19 disease. When detailing the results
of testing on the MoCA scale, in general, the examined patients were dominated
by changes in the executive function of drawing a broken line, optical-spatial
disorders, and worsening of delayed word reproduction (hearing-speech
memory). At the same time, auditory-verbal memory disorders were more often
observed in patients with MG.

Iqtiboslar

Baer, M. Neuroprotection: models, mechanisms, therapy / M. Baer. -

Moscow: BINOM. knowledge laboratory,2011. – P. 429.

Domashenko M.A., Maksimova M.Yu., Sergeev D.V., Piradov M.A. Citicoline

in the treatment of ischemic disorders of cerebral circulation // BC. 2013. № 30.

P. 1540–1542.

Lomonosov, O.V. Cerebral strokes: rehabilitation of patients and disabled

people of working age in the metropolis: Abstract of the thesis. cand. honey.

Sciences. / Lomonosova O.V. - St. Petersburg, 2021. – P. 24.

Sergeev D.V., Piradov M.A. Citicoline in the treatment of ischemic stroke -

new evidence of effectiveness // BC. 2012. № 31. P.1552–1554.

Nashr qilingan

2023-04-16

Iqtibos keltirish tartibi

CLINICAL EFFICACY OF COMBINED NEUROPROTECTION IN PATIENTS WITH COVID-19 DISEASE. (2023). Zamonaviy Dunyoda Ilm-Fan Va Texnologiya, 2(13), 65-68. https://in-academy.uz/index.php/ZDIFT/article/view/20711